Expertise in
35
conditions

Dr. Mark W. Jalkut

Urology
Associated Urologists Of North Carolina PA
3821 Ed Dr, 
Raleigh, NC 
 (788.3 mi)
Accepting New Patients
Offers Telehealth
Expertise in
35
conditions
Associated Urologists Of North Carolina PA
3821 Ed Dr, 
Raleigh, NC 
 (788.3 mi)
OverviewInsuranceLocationsClinical Research

Overview

Mark Jalkut is an Urologist in Raleigh, North Carolina. Dr. Jalkut is highly rated in 35 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Ureteroscopy, and Nephrectomy. Dr. Jalkut is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in NC
Hospital Affiliations
Johnston Health
Rex Hospital
Languages Spoken
English
Slovak
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Friday Health
  •  UnitedHealthcare
  •  Humana

Locations

ASSOCIATED UROLOGISTS OF NORTH CAROLINA PA
3821 Ed Dr, Raleigh, NC 27612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2024
Intervention Type: Drug
Study Drugs: ALT-803, Bacillus Calumette-Guerin
Study Phase: Phase 2/Phase 3
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
A Post-Market Evaluation of the Altis® Single Incision Sling System Versus Transobturator or Retropubic Mesh Sling in the Treatment of Female Stress Urinary Incontinence
A Post-Market Evaluation of the Altis® Single Incision Sling System Versus Transobturator or Retropubic Mesh Sling in the Treatment of Female Stress Urinary Incontinence
Enrollment Status: Completed
Publish Date: December 04, 2023
Intervention Type: Device
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: VERU-100
Study Phase: Phase 1/Phase 2
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Enrollment Status: Terminated
Publish Date: May 17, 2023
Intervention Type: Drug, Biological, Combination product
Study Phase: Phase 1/Phase 2
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
Enrollment Status: Active_not_recruiting
Publish Date: November 01, 2022
Intervention Type: Device
Study Phase: Not Applicable
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Enrollment Status: Terminated
Publish Date: June 23, 2022
Intervention Type: Diagnostic test
An Evaluation of the Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
An Evaluation of the Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
Enrollment Status: Terminated
Publish Date: May 13, 2022
Intervention Type: Other, Device
Study Phase: Not Applicable
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing Among Men With Prostate Cancer in the Community Urology Practice Setting
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing Among Men With Prostate Cancer in the Community Urology Practice Setting
Enrollment Status: Completed
Publish Date: November 05, 2020
View 9 Less Clinical Trials

6 Total Publications

Reply by Authors.
Reply by Authors.
Journal: The Journal of urology
Published: August 09, 2023
Similar Doctors
Expertise in
25
conditions
Dr. Glenn M. Preminger
Urology
Expertise in
25
conditions
Dr. Glenn M. Preminger
Urology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (18.4 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Glenn Preminger is an Urologist in Durham, North Carolina. Dr. Preminger is highly rated in 25 conditions, according to our data. His top areas of expertise are Kidney Stones, Urinary Tract Infection (UTI), Perirenal Abscess, Lithotripsy, and Ureteroscopy. Dr. Preminger is currently accepting new patients.

Expertise in
25
conditions
Dr. Michael E. Lipkin
Urology
Expertise in
25
conditions
Dr. Michael E. Lipkin
Urology

Duke Health Integrated Practice Inc

2301 Erwin Rd, 
Durham, NC 
 (18.5 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Lipkin is an Urologist in Durham, North Carolina. Dr. Lipkin is highly rated in 25 conditions, according to our data. His top areas of expertise are Kidney Stones, UPJ Obstruction, Perirenal Abscess, Lithotripsy, and Ureteroscopy. Dr. Lipkin is currently accepting new patients.

Expertise in
17
conditions
Dr. Daniel J. George
Urology | Hematology | Oncology
Expertise in
17
conditions
Dr. Daniel J. George
Urology | Hematology | Oncology

Duke Health Integrated Practice Inc

20 Duke Medicine Cir, 
Durham, NC 
 (18.4 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel George is an Urologist and a Hematologist in Durham, North Carolina. Dr. George is highly rated in 17 conditions, according to our data. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Orchiectomy. Dr. George is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile